Novo CEO signals M&A opportunities to strengthen drug pipeline
Novo CEO Mike Doustdar told CNBC that it is considering M&A opportunities as it faces growing competition in the weight-loss market.
ImpactNotable 35/100
Why it mattersRule-based estimate: event keywords (+6); trust 7/10.
RegionsGlobal
Published1 h ago (Tue, 22 Sep 2026 09:39:29 GMT)
RetrievedTue, 22 Sep 2026 10:00:50 GMT via rss
ClassifiedTue, 22 Sep 2026 10:00:55 GMT by heuristic